Chembio Diagnostics, Inc. (CEMI): Sharon W Klugewicz , Chief Operating Officer of Chembio Diagnostics, Inc. sold 3,000 shares on Jun 15, 2016. The Insider selling transaction was reported by the company on Jun 17, 2016 to the Securities and Exchange Commission. The shares were sold at $8.40 per share for a total value of $25,200.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 2, 2016, Javan Esfandiari (Chief Science/Tech Officer) sold 25,000 shares at $8.57 per share price.
Shares of Chembio Diagnostics Inc (CEMI) ended Wednesday, Jun 15, 2016 session in red amid volatile trading. The shares closed down -0.1 points or -1.15% at $8.6 with 64,454 shares getting traded. Post opening the session at $8.63, the shares hit an intraday low of $8.4 and an intraday high of $8.66 and the price vacillated in this range throughout the day. The company has a market cap of $83 M and the number of outstanding shares has been calculated to be 96,70,609 shares. The 52-week high of Chembio Diagnostics Inc is $9.4 and the 52-week low is $3.33.
Company has been under the radar of several Street Analysts.Chembio Diagnostics Inc is Reiterated by The Benchmark Company to Speculative Buy and the brokerage firm has raised the Price Target to $ 8 from a previous price target of $6 .The Rating was issued on Apr 18, 2016.
Chembio Diagnostics Inc. (Chembio) and its wholly owned subsidiary Chembio Diagnostic Systems Inc. develop manufacture market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s main products presently commercially available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples and are manufactured in a standard cassette format a dipstick format and a barrel format. Its Dual Path Platform (DPP) HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples as well as in all blood matrices. Additionally Chembio’s product pipeline includes a multiplex test that detects P24 HIV antigen as well as HIV 1/2 antibodies and a rapid test for the detection of Hepatitis-C antibodies.